Inozyme Pharma: A Closer Look at Executive Compensation Amid Strategic Developments

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company primarily focused on developing therapeutics for rare diseases affecting bone and blood vessel health, has garnered attention not only for its medical innovations but also for its executive compensation strategies. Over recent years, the company has experienced changes in its leadership team, with significant compensation packages reflecting the roles and responsibilities of its top executives.


For the fiscal year 2024, Douglas A. Treco, Ph.D., serving as the Chief Executive Officer and Chairman, received a total compensation of $2,485,392. This package included a base salary of $541,667 and an option award totaling $1,933,375, without any bonuses or stock awards reported. Such a substantial option award highlights the company's strategy to align the CEO’s interests with those of its shareholders, encouraging a focus on long-term growth and innovation in drug development.[^1]

Comparatively, the compensation structures of previous executives reflect slightly different compositions. For instance, in 2021, Axel Bolte, then President and CEO, was awarded a total compensation of $2,623,972, predominantly driven by an option award of $1,734,309 and a salary of $544,205, complemented by incentive plan compensation of $250,960. His total compensation structure was similar to Treco's, emphasizing options over cash bonuses, which is a common practice in the biotech sector to promote executive commitment to the company’s future success.[^2][^3]

Additionally, Sanjay S. Subramanian, the Senior Vice President and Chief Financial Officer in 2022, had a more diversified compensation package totaling $1,155,826. His package included a base salary of $337,385, bonuses, option awards, and incentive plan compensation, reflecting the varied responsibilities of the CFO in managing both financial health and strategic direction of the company.[^4]

Amid these executive changes, Inozyme has made significant strides in its clinical programs. Recent developments include the presentation of interim data on INZ-701 at the CHOP Cardiology Annual Meeting 2025, indicating the potential of this therapeutic in treating ENPP1 deficiency in infants and young children. This event, alongside other strategic communications, including participation in the 24th Annual Needham Virtual Healthcare Conference, underscores the company's proactive approach in sharing progress with investors and the medical community.[^5][^6]

Despite these advancements, the company recently reported a decrease in stock price, with shares trading at $1.26, reflecting a 15.44% decline in market value. The volatility in its share price indicates ongoing market evaluation of its clinical developments and financial strategies, with the broader market anticipating upcoming earnings announcements expected in May 2025.[^7]

As Inozyme continues to advance its clinical programs and navigate the complexities of biopharmaceutical innovation, executive compensation will likely remain a focal point for stakeholders assessing the company’s strategic alignment and leadership incentives.

---

:

[^1]: "Douglas A. Treco, Ph.D. - CEO Compensation Data," SEC Filing, [https://www.sec.gov/Archives/edgar/data/1693011/000095017025060198/0000950170-25-060198-index.htm](https://www.sec.gov/Archives/edgar/data/1693011/000095017025060198/0000950170-25-060198-index.htm).

[^2]: "Axel Bolte - 2021 CEO Compensation (Former)," SEC Filing, [https://www.sec.gov/Archives/edgar/data/1693011/000095017023015020/0000950170-23-015020-index.htm](https://www.sec.gov/Archives/edgar/data/1693011/000095017023015020/0000950170-23-015020-index.htm).

[^3]: "Axel Bolte - 2021 CEO Compensation," SEC Filing, [https://www.sec.gov/Archives/edgar/data/1693011/000119312522123568/0001193125-22-123568-index.htm](https://www.sec.gov/Archives/edgar/data/1693011/000119312522123568/0001193125-22-123568-index.htm).

[^4]: "Sanjay S. Subramanian - 2022 CFO Compensation," SEC Filing, [https://www.sec.gov/Archives/edgar/data/1693011/000095017024049229/0000950170-24-049229-index.htm](https://www.sec.gov/Archives/edgar/data/1693011/000095017024049229/0000950170-24-049229-index.htm).

[^5]: "Inozyme Pharma to Present at CHOP Cardiology 2025," GlobeNewswire, [https://www.globenewswire.com/news-release/2025/02/21/3030451/0/en/Inozyme-Pharma-to-Present-Recently-Announced-Interim-Data-for-INZ-701-in-Infants-and-Young-Children-with-ENPP1-Deficiency-at-CHOP-Cardiology-2025.html](https://www.globenewswire.com/news-release/2025/02/21/3030451/0/en/Inozyme-Pharma-to-Present-Recently-Announced-Interim-Data-for-INZ-701-in-Infants-and-Young-Children-with-ENPP1-Deficiency-at-CHOP-Cardiology-2025.html).

[^6]: "Inozyme Pharma Announces Presentation at Needham Conference," GlobeNewswire, [https://www.globenewswire.com/news-release/2025/03/31/3052294/0/en/Inozyme-Pharma-to-Participate-in-the-24th-Annual-Needham-Virtual-Healthcare-Conference.html](https://www.globenewswire.com/news-release/2025/03/31/3052294/0/en/Inozyme-Pharma-to-Participate-in-the-24th-Annual-Needham-Virtual-Healthcare-Conference.html).

[^7]: "Inozyme Pharma Stock Price Snapshot," [https://www.nasdaq.com/market-activity/stocks/inzy](https://www.nasdaq.com/market-activity/stocks/inzy).